<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444275</url>
  </required_header>
  <id_info>
    <org_study_id>D9612L00111</org_study_id>
    <secondary_id>EudraCT No: 2006-002867-19</secondary_id>
    <nct_id>NCT00444275</nct_id>
  </id_info>
  <brief_title>Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>A Randomized, Open, Parallel-group Study to Evaluate the Efficacy of Three Different Patient Management Strategies During a 12 Weeks Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of three different long-term treatment strategies of reflux disease
      in primary care setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Three Strategies of Long-term Treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ).</measure>
    <time_frame>4 weeks</time_frame>
    <description>Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator.
The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From &quot;Never&quot; for the Lowest Frequency to &quot;Every Day&quot; for the Highest, 6 Others Assess the Severity of Symptoms From &quot;Not at All&quot; to &quot;Strong&quot;. The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Treatment With Low Dose Aspirin (Acetyl Salicylic Acid) Used Concomitantly During the Initial Phase and the Maintenance Phase</measure>
    <time_frame>4 weeks</time_frame>
    <description>No possibility to describe as only 2 patients took ASA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase)</measure>
    <time_frame>4 to 16 weeks</time_frame>
    <description>Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ [8-10] : possible anxiety-depression/ &gt;10 : anxiety-depression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study</measure>
    <time_frame>12 weeks - maintenance treatment phase</time_frame>
    <description>Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <description>May be used to evaluate the severity of symptoms during the initial visit. Not done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <description>May be used to offer patients a strategy of treatment during the initial phase and in the long term.
Not done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ)</measure>
    <time_frame>Week 4</time_frame>
    <description>May be used to define the success of treatment. Not done</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3029</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Esomeprazole 20 mg Once Daily (initial phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40 mg Once Daily (initial phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 20 mg Once Daily (Maintenance Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 20 mg on Demand (Maintenance Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antacid Treatment (Maintenance Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole (Nexium®)</intervention_name>
    <description>This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed</description>
    <arm_group_label>Esomeprazole 20 mg Once Daily (initial phase)</arm_group_label>
    <arm_group_label>Esomeprazole 40 mg Once Daily (initial phase)</arm_group_label>
    <arm_group_label>Esomeprazole 20 mg Once Daily (Maintenance Phase)</arm_group_label>
    <arm_group_label>Esomeprazole 20 mg on Demand (Maintenance Phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xolaam®</intervention_name>
    <description>This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed</description>
    <arm_group_label>Antacid Treatment (Maintenance Phase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who seek medical advice in primary care for symptoms thought to be GERD
             related (GERD is a condition which develops when the reflux of stomach content causes
             troublesome symptoms and / or complications).

        Exclusion Criteria:

          -  Subjects with any clinical GERD treatment (PPI, H2-receptor antagonists) within the
             last 3 months prior to Visit 1.

          -  A history of severe esophagitis or known other complications, with alarm symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca France Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>AstraZeneca Clinical Trial Information - Outside US</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <results_first_submitted>March 29, 2010</results_first_submitted>
  <results_first_submitted_qc>November 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2012</results_first_posted>
  <last_update_submitted>November 14, 2012</last_update_submitted>
  <last_update_submitted_qc>November 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal Reflux Disease</keyword>
  <keyword>Acid Reflux</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Antacids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited by general practitioner between March 1, 2007 and July 21, 2008</recruitment_details>
      <pre_assignment_details>The study included 2 phases (maximum treatment duration = 16 weeks):
one initial treatment phase of 4 weeks
one randomized maintenance treatment phase of 12 weeks only for patients whose initial treatment is considered to be successful at the end of the initial phase.
Only maintenance phase data were reported in the Baseline module measures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
        </group>
        <group group_id="P2">
          <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
        </group>
        <group group_id="P3">
          <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
        </group>
        <group group_id="P4">
          <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
        </group>
        <group group_id="P5">
          <title>Antacid Treatment (Maintenance Phase)</title>
          <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2156"/>
                <participants group_id="P2" count="873"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1908"/>
                <participants group_id="P2" count="777"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Maintenance Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="908"/>
                <participants group_id="P4" count="897"/>
                <participants group_id="P5" count="880"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="747"/>
                <participants group_id="P4" count="764"/>
                <participants group_id="P5" count="701"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="133"/>
                <participants group_id="P5" count="179"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn'r receive the treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol specific criteria's development</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's wish</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineffectiveness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
        </group>
        <group group_id="B2">
          <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
        </group>
        <group group_id="B3">
          <title>Antacid Treatment (Maintenance Phase)</title>
          <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="871"/>
            <count group_id="B2" value="857"/>
            <count group_id="B3" value="830"/>
            <count group_id="B4" value="2558"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="9.83"/>
                    <measurement group_id="B2" value="41.79" spread="9.97"/>
                    <measurement group_id="B3" value="41.6" spread="10"/>
                    <measurement group_id="B4" value="41.64" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="415"/>
                    <measurement group_id="B3" value="411"/>
                    <measurement group_id="B4" value="1275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                    <measurement group_id="B2" value="442"/>
                    <measurement group_id="B3" value="419"/>
                    <measurement group_id="B4" value="1283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Three Strategies of Long-term Treatment</title>
        <description>Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O3">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Three Strategies of Long-term Treatment</title>
          <description>Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?</description>
          <units>Percentage of participants with failure</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="871"/>
                <count group_id="O2" value="857"/>
                <count group_id="O3" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="7.8"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ).</title>
        <description>Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator.
The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From &quot;Never&quot; for the Lowest Frequency to &quot;Every Day&quot; for the Highest, 6 Others Assess the Severity of Symptoms From &quot;Not at All&quot; to &quot;Strong&quot;. The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ).</title>
          <description>Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator.
The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From &quot;Never&quot; for the Lowest Frequency to &quot;Every Day&quot; for the Highest, 6 Others Assess the Severity of Symptoms From &quot;Not at All&quot; to &quot;Strong&quot;. The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1909"/>
                <count group_id="O2" value="778"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Treatment With Low Dose Aspirin (Acetyl Salicylic Acid) Used Concomitantly During the Initial Phase and the Maintenance Phase</title>
        <description>No possibility to describe as only 2 patients took ASA</description>
        <time_frame>4 weeks</time_frame>
        <population>Outcome measure not possible to describe as only 2 patients took Aspirin.</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Treatment With Low Dose Aspirin (Acetyl Salicylic Acid) Used Concomitantly During the Initial Phase and the Maintenance Phase</title>
          <description>No possibility to describe as only 2 patients took ASA</description>
          <population>Outcome measure not possible to describe as only 2 patients took Aspirin.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase)</title>
        <description>Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)</description>
        <time_frame>4 to 16 weeks</time_frame>
        <population>871 (-66 missing data, 801 (-56 missing data), 833 (-75 missing data)</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase)</title>
          <description>Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)</description>
          <population>871 (-66 missing data, 801 (-56 missing data), 833 (-75 missing data)</population>
          <units>Scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="871"/>
                <count group_id="O4" value="801"/>
                <count group_id="O5" value="833"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.12" spread="0.79"/>
                    <measurement group_id="O4" value="0.04" spread="0.73"/>
                    <measurement group_id="O5" value="-0.22" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment</title>
        <description>Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ [8-10] : possible anxiety-depression/ &gt;10 : anxiety-depression)</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment</title>
          <description>Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ [8-10] : possible anxiety-depression/ &gt;10 : anxiety-depression)</description>
          <units>Percent of participants with failure</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="871"/>
                <count group_id="O4" value="857"/>
                <count group_id="O5" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="9.8"/>
                    <measurement group_id="O4" value="9.3"/>
                    <measurement group_id="O5" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study</title>
        <description>Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.</description>
        <time_frame>12 weeks - maintenance treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study</title>
          <description>Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="886"/>
                <count group_id="O4" value="880"/>
                <count group_id="O5" value="851"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</title>
        <description>May be used to evaluate the severity of symptoms during the initial visit. Not done</description>
        <time_frame>Day 0</time_frame>
        <population>The results of exploratory analyses are not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</title>
          <description>May be used to evaluate the severity of symptoms during the initial visit. Not done</description>
          <population>The results of exploratory analyses are not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</title>
        <description>May be used to offer patients a strategy of treatment during the initial phase and in the long term.
Not done</description>
        <time_frame>Day 0</time_frame>
        <population>The results of exploratory analyses are not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire</title>
          <description>May be used to offer patients a strategy of treatment during the initial phase and in the long term.
Not done</description>
          <population>The results of exploratory analyses are not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ)</title>
        <description>May be used to define the success of treatment. Not done</description>
        <time_frame>Week 4</time_frame>
        <population>The results of exploratory analyses are not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
          </group>
          <group group_id="O4">
            <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
          </group>
          <group group_id="O5">
            <title>Antacid Treatment (Maintenance Phase)</title>
            <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Score Abacuses Based on the Reflux Disease Questionnaire (RDQ)</title>
          <description>May be used to define the success of treatment. Not done</description>
          <population>The results of exploratory analyses are not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Esomeprazole 20 mg Once Daily (Initial Phase)</title>
        </group>
        <group group_id="E2">
          <title>Esomeprazole 40 mg Once Daily (Initial Phase)</title>
        </group>
        <group group_id="E3">
          <title>Esomeprazole 20 mg Once Daily (Maintenance Phase)</title>
        </group>
        <group group_id="E4">
          <title>Esomeprazole 20 mg on Demand (Maintenance Phase)</title>
        </group>
        <group group_id="E5">
          <title>Antacid Treatment (Maintenance Phase)</title>
          <description>antacid treatment as needed (maintenance phase) (Xolaam® maximum six tablets per day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE BALTHAZAR E PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>EROSIVE ANTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>ADENOMATOUS POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PREEXISTING LUNG CARCINOMA AGGRAVATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>DIGESTIVE VIROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>AGGRAVATION OF INTERVERTEBRAL DISC HERNIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHE SIS AGGRAVATION BY L5 SPONDYLOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRONCHIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOM A OF GASTRIC ANTRUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>CARCINOMA OF OESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIO-DEPRESSI VE STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>DEPRESSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Pharyngeal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="880"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="851"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Planned number of patients not reached: statistical analysis plan revised,comparisons between treatment arms performed globally (No stratified analysis).
Safety pop=3032-3 incorrect enrolments (withdrawals at V2) with no information on ttmt received</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

